title: Effect of Y-27632 on release of cytokines from peripheral T cells in asthmatic patients and normal subjects.
abstract: Previously we have reported that Y-27632, a selective inhibitor of Rho-associated protein kinases (ROCKs) for RhoA, suppressed concanavalin A (Con A)-induced secretion of cytokines from peripheral T cells of normal persons. Recent studies suggested its usefulness for clinical management of bronchial asthma. We examined effect of Y-27632 on release of cytokines from T cells of asthmatic patients. Peripheral T cells of six asthmatic subjects and six normal persons were stimulated with Con A for 24 h in the presence of Y-27632. The concentrations of IL-2, interferon (IFN)-gamma, IL-4, and IL-5 in supernatant were measured. Y-27632 down-regulated secretion of IL-2 and IFN-gamma and weakly decreased secretion of IL-4 and IL-5 from Con A-activated T cells in the asthmatics. The reduced secretion of IFN-gamma and IL-4 in the asthmatics was inferior to that in the normal subjects. Our data suggested that the involvement of RhoA/ROCK pathway in TCR-mediated secretion of IFN-gamma and IL-4 in patients with bronchial asthma differed from that in healthy persons.
authors.affiliation: First Department of Internal Medicine, Faculty of Medicine, School of Medicine, Gunma University, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511, Japan. aiharam@showa.gunma-u.ac.jp
authors.forename: Masayuki
authors.initials: M
authors.lastname: Aihara
authors.forename: Kunio
authors.initials: K
authors.lastname: Dobashi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Iizuka
authors.forename: Tsugio
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Masatomo
authors.initials: M
authors.lastname: Mori
mesh_terms: D000328:Adult; D000577:Amides / Q000008:administration & dosage / Q000494:pharmacology*; D001249:Asthma / Q000276:immunology / Q000378:metabolism*; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D015848:Interleukin-5 / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D018417:Th1 Cells / Q000378:metabolism; D018418:Th2 Cells / Q000378:metabolism; D054460:rho-Associated Kinases
chemical_list: D000577:Amides; D016207:Cytokines; D007376:Interleukin-2; D015848:Interleukin-5; D047908:Intracellular Signaling Peptides and Proteins; D011725:Pyridines; D003208:Concanavalin A; C108830:Y 27632; D015847:Interleukin-4; D007371:Interferon-gamma; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases